A Medical Device Daily

Merit Medical Systems (South Jordan, Utah), a manufacturer of disposable devices used primarily in cardiology, radiology and gastroenterology procedures, said it has completed a three-part deal with Vysera Biomedical (Galway, Ireland), which will give Merit access to certain intellectual property and know-how for valve technology, opportunities to commercialize certain biomaterial technology and equity ownership in Vysera.

The total amount paid by Merit to Vysera in license fees and equity purchase payments is roughly $3.9 million.

The transactions provide Merit with an exclusive license for certain valve technology that may be incorporated into non-vascular stents, specifically esophageal stents, to address acid reflux conditions. Secondly, the transactions provide Merit with an exclusive license for the development and use of certain biomaterial technology for the coating of selected non-vascular stents and gastrointestinal and drainage catheters.

Finally, the transactions provide Merit with an equity investment of about $2.4 million, which will give the company almost 14.45% fully-diluted participating equity interest in Vysera. Fred Lampropoulos, Merit's CEO and chairman, has been elected as a director of Vysera.

"We are pleased to join the Enterprise Equity Investment Fund Limited, Enterprise Ireland, the Western Development Commission and other Vysera investors in what we believe are cutting-edge device and biomaterial opportunities," Lampropoulos said. "We believe the licensed technologies will be beneficial for products developed for Merit's Endotek division as well as our interventional radiology product group."

"We look forward to the association with Mr. Lampropoulos and Merit Medical Systems," said Donal Devery, CEO of Vysera. "Their long record of innovation and growth in addition to their marketing resources with global reach will expedite the commercialization of our technology in the medical device market."